Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for NextBioMedical Co., Ltd. (389650:KRX), powered by AI.
NextBioMedical Co., Ltd. is currently trading at ₩44,900. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for NextBioMedical Co., Ltd. on Alpha Lenz.
NextBioMedical Co., Ltd.'s P/E ratio is -1194.7.
“NextBioMedical Co., Ltd. trades at a P/E of -1194.7 (undervalued) with modest ROE of -0.7%. 3Y revenue CAGR of 80.6% highlights clear growth momentum.”
Ask for details →NextBioMedical Co., Ltd. is a distinguished entity in the healthcare and medical device industry. Specializing in the development and production of cutting-edge biomedical technologies, its primary purpose is to enhance patient care and improve clinical outcomes. The company's product portfolio includes advanced medical devices for various therapeutic applications, focusing on minimally invasive solutions that cater to cardiovascular, orthopedic, and surgical needs. NextBioMedical Co., Ltd. operates at the intersection of healthcare innovation and technological advancement, continually pushing the envelope in terms of efficacy and safety in medical treatments. The firm is integral to the broader medical device market, driven by an increasing demand for innovative healthcare solutions. Headquartered in South Korea, NextBioMedical is influential in both local and international markets, reflecting its commitment to quality and global health improvement. As part of the industrial biosciences ecosystem, it plays a critical role in advancing medical technology, contributing to life-saving innovations and the future of healthcare.
“NextBioMedical Co., Ltd. trades at a P/E of -1194.7 (undervalued) with modest ROE of -0.7%. 3Y revenue CAGR of 80.6% highlights clear growth momentum.”
Ask for details →NextBioMedical Co., Ltd. (ticker: 389650) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $371.7B.
The current price is ₩44,900 with a P/E ratio of -1,194.7x and P/B of 7.73x.
ROE is -0.67% and operating margin is -4.37%. Annual revenue is $16.5B.